Paper card · curated
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, et al.
British Journal of Pharmacology · 2013
Abstract excerpt
CBDA, the acidic precursor of CBD, was investigated in preclinical models of vomiting (Suncus murinus) and nausea-induced conditioned gaping (rats). CBDA was substantially more potent than CBD on a per-mg basis at suppressing both phenomena, mediated through enhanced 5-HT1A receptor activation. The findings are consistent with growing evidence that CBDA has its own pharmacology distinct from its decarboxylated form CBD, particularly at serotonergic targets.
Excerpt from the published abstract. Full paper at the journal link below.
Joe's notes
How to read this paper
Foundational CBDA paper. Read alongside Pellesi 2018 (oral pharmacokinetics) for the full picture of why the acidic form matters at the molecular level. Most CBD products on shelves today contain mostly decarboxylated CBD — extraction-side decisions can shift that.
Read the paper
FDA disclaimer
Research papers in this library describe published scientific findings. They are not therapeutic claims. These statements have not been evaluated by the FDA. Compounds discussed in any paper are not intended to diagnose, treat, cure, or prevent any disease. Talk to a healthcare provider before making decisions about supplements.